Welcome to our dedicated page for Tempus AI SEC filings (Ticker: TEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
Tempus AI (TEM) Q2 2025 10-Q highlights:
- Revenue doubled to $314.6 M (+89% YoY); Genomics up 115% to $241.8 M and Data & Services up 36% to $72.8 M.
- Losses narrowed sharply. Net loss was $42.8 M vs. $552.2 M prior-year; loss per share improved to $(0.25) from $(6.86). Six-month loss fell 82% to $110.9 M.
- Margin trend: Gross margin rose to 62.0% from 45.5% as revenue growth outpaced cost of revenue.
- Cash flow improving. Operating cash outflow was $61.5 M versus $198.5 M YoY.
- Balance sheet transformed by M&A. Ambry Genetics acquisition (closed Feb 2025) added $695 M in assets, boosting goodwill/intangibles to $713 M. Total assets $1.63 B (+76% YTD); equity $309.6 M vs. $56.3 M at YE-24.
- Leverage increased. Long-term debt rose to $471.7 M (including new $100 M revolver); convertible note now $226.3 M. Cash & equivalents declined to $186.3 M from $341.0 M due to acquisition spend.
- The company remains an emerging growth company but expects to become a large accelerated filer as of year-end 2025.
Outlook implications: Rapid top-line expansion and integration of Ambry broaden TEM’s test menu and dataset, but higher leverage and ongoing losses keep profitability and liquidity key watch points.
Tempus AI, Inc. (Nasdaq: TEM) furnished a Form 8-K stating that on August 8, 2025 the company issued a press release with its financial results for the quarter ended June 30, 2025, which is furnished as Exhibit 99.1. The company also made supplemental financial information and a letter from its Chief Executive Officer and Chief Financial Officer available on the "Events" page of its investor relations website at http://investors.tempus.com. The filing explicitly states these materials are furnished, not filed, and includes Exhibit 104, the Cover Page Interactive Data File (Inline XBRL). The Form 8-K is signed by James Rogers, Chief Financial Officer, and the registrant is identified as an emerging growth company with Class A common stock trading under the symbol TEM on The Nasdaq Stock Market.
Tempus AI (TEM) Form 4: CEO/Chairman Eric P. Lefkofsky reported the sale of 166,250 Class A shares on 28-Jul-2025 under a Rule 10b5-1 trading plan adopted 4-Mar-2025.
- Gray Media, LLC – 33,250 shares sold at weighted averages of $62.16-$65.23; post-sale position: 9,274,033 shares.
- Blue Media, LLC – 133,000 shares sold at the same price ranges; post-sale position: 18,135,469 shares.
After these transactions, Lefkofsky remains the beneficial owner of ~39.8 million shares (2.04 M direct, 27.4 M via Gray/Blue Media and 10 M through a 2025 GRAT plus smaller entities), preserving an overwhelming majority of his stake.
No derivative transactions were reported. The filing notes that detailed price breakdowns are available upon request and that some direct shares were recently transferred to Blue Media.
Takeaway: While any insider sale by the founder can draw attention, the divested amount equals ≈0.4 % of his disclosed holdings, suggesting portfolio rebalancing rather than a meaningful reduction in commitment.